What is one common genetic factor that can lead to resistance to non-steroidal anti-inflammatory drugs (NSAIDs)?
Master all 22 flashcards
Explore reasons why some patients do not respond to therapy and potential strategies to overcome resistance.
By mastering this deck, learners will understand the underlying mechanisms of anti-inflammatory resistance, enabling them to identify causes of non-responsiveness and tailor more effective treatment strategies in clinical practice.
ℹ️ Educational Use Only: This flashcard deck is created by usersof our platform for their educational and study purposes. The content is not intended as medical advice, diagnosis, or treatment guidance. Always consult qualified healthcare professionals for medical decisions and verify information with authoritative medical sources.
Showing 20 of 22 cardsSample view
| # | Front | Back | Hint |
|---|---|---|---|
| 1 | What is one common genetic factor that can lead to resistance to non-steroidal anti-inflammatory drugs (NSAIDs)? | Genetic polymorphisms in cyclooxygenase (COX) enzymes, such as COX-2 variants, can reduce drug efficacy by altering enzyme sensitivity or expression levels. | Think about enzyme variants affecting drug targets. |
| 2 | How can overexpression of drug efflux transporters contribute to resistance to anti-inflammatory drugs? | Overexpression of efflux transporters like P-glycoprotein (P-gp) can pump anti-inflammatory drugs out of cells, decreasing intracellular drug concentrations and reducing effectiveness. | Consider the role of cellular 'pumps' in drug resistance. |
| 3 | Name an example of a cellular mechanism that leads to decreased sensitivity to corticosteroids. | Reduced expression or function of the glucocorticoid receptor (GR), often due to receptor mutations or downregulation, diminishes the cellular response to corticosteroids. | Think about the receptor required for steroid action. |
| 4 | What role does cytokine milieu play in resistance to anti-inflammatory therapies? | A pro-inflammatory cytokine environment can upregulate alternative inflammatory pathways, diminishing the effectiveness of targeted anti-inflammatory agents. | Consider how inflammation can adapt to evade therapy. |
| 5 | How can chronic use of NSAIDs lead to pharmacodynamic tolerance? | Chronic NSAID use can cause downregulation or desensitization of COX enzymes or receptor pathways, reducing drug efficacy over time. | Think about the body's adaptive responses to prolonged drug exposure. |
| 6 | Describe how alternative inflammatory pathways can cause non-responsiveness to a specific anti-inflammatory agent. | If an anti-inflammatory targets a particular pathway (e.g., COX-2), activation of parallel pathways (e.g., lipoxygenase pathway) can sustain inflammation, rendering the drug less effective. | Remember redundant inflammatory pathways. |
| 7 | What is the significance of drug metabolism variability in resistance to anti-inflammatory drugs? | Genetic differences in drug-metabolizing enzymes (e.g., CYP450 isoforms) can lead to rapid clearance or reduced activation of prodrugs, decreasing therapeutic levels. | Think about how metabolism affects drug levels. |
| 8 | How can adherence issues lead to perceived non-responsiveness to anti-inflammatory therapy? | Poor medication adherence or incorrect dosing can result in subtherapeutic drug levels, making it seem like the patient is resistant when they are not properly compliant. | Consider patient behavior as a factor. |
| 9 | What strategies can be employed to overcome pharmacodynamic resistance to anti-inflammatories? | Strategies include dose escalation, combination therapy targeting multiple pathways, or switching to drugs with different mechanisms of action. | Think about multi-pronged approaches. |
| 10 | Why might some patients exhibit non-responsiveness to corticosteroids despite adequate dosing? | Possible reasons include glucocorticoid receptor mutations, decreased receptor expression, or increased expression of anti-inflammatory cytokines that counteract steroid effects. | Receptor insensitivity is a key factor. |
| 11 | How can inflammation-induced changes in receptor expression contribute to resistance? | Chronic inflammation can lead to downregulation or altered expression of receptors necessary for drug action, reducing responsiveness. | Consider receptor regulation in chronic disease. |
| 12 | What is the impact of drug-drug interactions on resistance to anti-inflammatory therapy? | Certain drugs can induce or inhibit metabolic enzymes or transporters, reducing anti-inflammatory drug levels or effectiveness, leading to apparent resistance. | Think about how other medications modify drug pharmacokinetics. |
| 13 | Can epigenetic modifications influence resistance to anti-inflammatories? If so, how? | Yes, epigenetic changes like DNA methylation or histone modification can alter the expression of inflammatory mediators or drug targets, impacting drug responsiveness. | Recall gene expression regulation beyond genetics. |
| 14 | What role does the presence of comorbid conditions (e.g., obesity, diabetes) play in anti-inflammatory resistance? | Comorbidities can alter inflammatory pathways, increase baseline inflammation, and affect drug pharmacokinetics, potentially reducing drug efficacy. | Consider how systemic conditions influence inflammation. |
| 15 | How might bioavailability issues cause apparent resistance to oral anti-inflammatory drugs? | Poor absorption, gastrointestinal issues, or malabsorption syndromes can reduce drug levels reaching systemic circulation, leading to ineffective therapy. | Think about factors affecting drug intake. |
| 16 | What is an example of a pathway that can be upregulated in resistance, compensating for inhibited pathways? | The lipoxygenase pathway can be upregulated when COX pathways are inhibited, maintaining inflammatory mediator production. | Remember pathway redundancy in inflammation. |
| 17 | How can targeted therapy modifications help in overcoming resistance? | Switching to or combining with drugs that target alternative pathways or mechanisms can bypass resistance and restore anti-inflammatory effects. | Think personalized or adaptive therapy. |
| 18 | What is the significance of receptor polymorphisms in predicting patient response to anti-inflammatory drugs? | Receptor polymorphisms can alter drug binding or receptor activation, influencing the degree of response or resistance in individual patients. | Genetic variability is key. |
| 19 | In clinical practice, how can monitoring help address non-responsiveness to anti-inflammatory therapy? | Regular assessment of drug levels, inflammatory markers, and patient compliance can identify causes of non-response and guide therapy adjustments. | Combine pharmacokinetic and clinical monitoring. |
| 20 | What is the role of cytokine inhibitors in overcoming resistance caused by cytokine milieu alterations? | Cytokine inhibitors (e.g., anti-TNF agents) can block alternative pathways driving inflammation, especially when standard anti-inflammatory drugs fail. | Think about biologic agents targeting cytokines. |
Note: This preview shows only the first 20 cards. The complete deck contains 22 total cards. Start studying to access all flashcards.
Master all 22 flashcards
Explore other decks you might find helpful